BRIEF REPORTS: PDF OnlyAssociation study of a cannabinoid receptor gene (CNR1) polymorphism and schizophreniaTsai, Shih-Jena,b; Wang, Ying-Chiehc; Hong, Chen-Jeea,bAuthor Information aDepartment of Psychiatry, Veterans General Hospital-Taipei, Taipei, Taiwan;bDivison of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan;cSection of Psychiatry, Yu-Li Veterans Hospital, Hualien, Taiwan Correspondence to Shih-Jen Tsai MD, Department of Psychiatry, Veterans General Hospital-Taipei, No. 201, Shih-Pai Road, Sec. 2, 11217, Taipei, Taiwan. E-mail:[email protected] Received 5 June 2000; accepted 9 October 2000 Psychiatric Genetics: September 2000 - Volume 10 - Issue 3 - p 149-151 Buy Abstract Cannabis can induce schizophrenic-like symptoms in healthy individuals. A principal active ingredient of cannabis, delta-9-tetrahydrocannabinol, acts in the brain on a specific receptor, termed the cannabinoid receptor 1 (CNR1). The human gene for CNR1 is mapped to chromosome 6q14-15, and linkage studies have produced evidence for a schizophrenia-susceptibility locus in this region. To explore a possible role for CNR1 in the pathogenesis of schizophrenic disorders, we used an association study to genotype the CNR1 polymorphism for 127 schizophrenic patients and 146 control subjects. The results demonstrate no association between CNR1 genotypes and schizophrenic disorders (P= 0.409), with these negative findings suggesting that, for Chinese populations, the (AAT)n triplet repeat in the promoter region of the CNR1 gene is not directly involved in the pathogenesis of schizophrenic disorders. © 2000 Lippincott Williams & Wilkins, Inc.